Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 93 Carcinoma, Non-Small-Cell Lung 46 Neoplasms 33 Carcinoma, Renal Cell 24 Neoplasm Metastasis 16 Colorectal Neoplasms 13 Carcinoma, Hepatocellular 12 Small Cell Lung Carcinoma 9 Prostatic Neoplasms 9 Lung Neoplasms 9 Diabetes Mellitus, Insulin-Dependent, 12 9 Advanced Cancer 9 Squamous Cell Carcinoma of Head and Neck 8 Uveal Melanoma 7 Stomach Neoplasms 7 Skin Neoplasms 7 Mesothelioma 7 Kidney Neoplasms 7 Carcinoma, Transitional Cell 7 Recurrence 6 Pancreatic Neoplasms 6 Liver Neoplasms 6 Triple Negative Breast Neoplasms 5 Sarcoma 5 Ovarian Neoplasms 5 Head and Neck Neoplasms 5 Endometrial Neoplasms 5 Breast Neoplasms 5 Uterine Cervical Neoplasms 4 Solid Tumor 4

Interventions

Paclitaxel 2 vorolanib 1 spartalizumab 1 rucaparib 1 relatlimab 1 linrodostat 1 camrelizumab 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Gastric Cancer × Ipilimumab × Clear all

NCT02935634 2023-06-09

FRACTION-GC

Bristol-Myers Squibb

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡